Type 2 Diabetes

According to a study presented at the American Association of Clinical Endocrinology Annual Meeting 2025, patients with type 2 diabetes face significantly lower bone mineral density and an increased risk of...

At the Practical Updates in Primary Care 2025 conference, Julianne Blythe, MPA, PA-C, RPSGT, outlined practical strategies for identifying and managing obstructive sleep apnea, emphasizing screening tools,...

A study assesses whether the dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin reduces ischemic events in diabetes and kidney disease.

Individuals with prediabetes who achieve a weight loss of at least 5% experience significant improvements in insulin sensitivity and reductions in visceral fat, suggesting that remission of prediabetes can...

In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing patients with diabetes and the value of utilizing the services of a...

Researchers examined the risk of nephrolithiasis among patients with type 2 diabetes using SGLT2is for treatment.

Researchers investigated semaglutide’s impact on weight-related muscle loss and its potential impact on spinal surgical outcomes, specifically transforaminal lumbar interbody fusion.

Researchers sought to determine whether patients with type 2 diabetes and obesity experience continued type 2 diabetes remission.

On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...

In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing people with diabetes, the importance of diabetes self-care and...